Quantcast
Last updated on April 16, 2014 at 13:58 EDT

Latest Liposome Stories

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-19 11:40:00

Enzyme-equipped liposomes embedded in polymer capsules as a novel biomedical transport system When cells cannot carry out the tasks required of them by our bodies, the result is disease. Nanobiotechnology researchers are looking for ways to allow synthetic systems take over simple cellular activities when they are absent from the cell. This requires transport systems that can encapsulate medications and other substances and release them in a controlled fashion at the right moment. The...

9cf673fffbe73dc7a647ed9be85ffe5f
2009-05-04 07:23:35

Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs "” small interfering RNA (siRNA) molecules that silence genes "” the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials. "RNA interference is a promising approach for prevention and treatment of human disease," said lead author Kim Woodrow, Yale...

2009-04-22 07:00:00

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in consolidation treatment for leukemia and of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado (Abstracts 4568 and 4578)....

2009-04-21 09:00:00

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the...

2009-04-16 07:23:54

 Researchers at Children's Hospital Boston have developed a slow-release anesthetic drug-delivery system that could potentially revolutionize treatment of pain during and after surgery, and may also have a large impact on chronic pain management.In NIH-funded work, they used specially designed fat-based particles called liposomes to package saxitoxin, a potent anesthetic, and produced long-lasting local anesthesia in rats without apparent toxicity to nerve or muscle cells. The research...

2009-02-06 09:09:41

Scientists including one from The University of Texas Health Science Center at Houston successfully predicted the outcome of a nano drug on breast tumors in a pre-clinical study. Their research could help determine which patients will respond best to cancer-fighting nano drugs.Researchers from the Georgia Institute of Technology and Emory University also participated in the study, which appears in the February issue of Radiology.The investigators used contrast agents encapsulated in tiny fat...

2008-10-16 09:00:42

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced the signing of a joint research agreement focusing on a new cancer treatment that combines Philips' ultrasound technology with Celsion's drug delivery solution to target tumors with high concentrations of a cancer-fighting drug. Under the terms of the agreement, Philips and Celsion will collaborate to explore the potential for using Philips' investigational magnetic resonance imaging...

2008-09-24 15:01:01

CELSION CORPORATION (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned. In addition to the receipt of FDA agreement in January of 2008 for our pivotal Phase III Primary Liver Cancer trial in the United States, the Company reports that it has obtained regulatory approval to conduct its study titled "A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox(R) (Thermally Sensitive Liposomal...

2008-09-08 09:00:08

BRIDGEWATER, N.J., Sept. 8 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL(R) (doxorubicin HCl liposome injection) and Taxotere(R) (docetaxel)* for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. The application to the FDA follows the completion of a randomized, parallel-group,...